mRNA COVID-19 vaccinations are not associated with RVO development 21 days and 12 weeks after vaccination.

Case reports have speculated if COVID-19 vaccinations may be associated with retinal vascular occlusions (RVO). Specifically, previous literature speculated an increased risk of RVOs days to weeks after vaccination. After reviewing two recent analyses, mRNA COVID-19 vaccinations do not appear to increase the risk of RVOs at 3 and 12 weeks post-vaccination.

Progressive maculopathy in a child resulting from vitreopapillary traction on a congenitally anomalous nerve.

Purpose: To present a case of worsening maculopathy and vision loss due to vitreopapillary traction associated with an anomalous optic nerve head in a pediatric patient successfully managed with pars plana vitrectomy.

Methods: Retrospective case report.

Results: A 13-year-old boy presented with unilateral maculopathy that slowly progressed over a four-year period.

Revisiting acute retinal pigment epitheliitis (Krill disease).

We reevaluate acute retinal pigment epitheliitis (ARPE) first described by Krill and Deutman in 1972, integrating a meticulous literature review with advanced multimodal imaging analyses. Our review included 98 eyes from 86 published cases diagnosed with ARPE. We scrutinized ARPE's clinical presentations, variability, and imaging characteristics, revealing that a large majority (90 %) of cases previously diagnosed as ARPE align more closely with other retinal disorders based on modern diagnostic criteria and imaging techniques.

Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40.

Purpose: To identify factors for meeting prespecified criteria for switching from bevacizumab to aflibercept in eyes with center-involved diabetic macular edema (CI-DME) and moderate vision loss initially treated with bevacizumab in DRCR Retina Network protocol AC.

Design: Post hoc analysis of data from a randomized clinical trial.

Participants: Two hundred seventy participants with one or both eyes harboring CI-DME with visual acuity (VA) letter score of 69 to 24 (Snellen equivalent, 20/50-20/320).